In a recent filing, Stewart Michael Paul has made an important update regarding his stock options. The filing, submitted on October 27, 2026, corrects the expiration date of a stock option to October 23, 2036. This change emphasizes the commitment of executives to align their compensation with the long-term performance of the company.

The update is significant as it showcases transparency and governance practices within Ionetix Corp, where Paul is a director. Such practices are essential for maintaining investor confidence in the company and the broader in vitro and in vivo diagnostic substances industry.

Background

Stewart Michael Paul is associated with Ionetix Corp, a company classified under the in vitro and in vivo diagnostic substances sector. The company, which operates under the CIK number 0002108121, is incorporated in Delaware. Its recent filings include a Form 4 and Form 3, indicating ongoing activity in executive transactions.

What the Filing Says

The filing states, "This Form 4/A is being filed to correct the expiration date of the Stock Option (Right to Buy), which was inadvertently reported as 10/23/2026 in the original Form 4 filed on 10/27/2026. The correct expiration date is 10/23/2036." This correction highlights the importance of accurate reporting in executive compensation.

Impact

This update may affect shareholders and stakeholders involved with Ionetix Corp, as it reflects the company's commitment to transparency and proper governance. The correction also reinforces the role of executives in ensuring that their compensation aligns with the company's long-term goals.

What's Next

The filing does not say what happens next.